Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Volixibat - Mirum Pharmaceuticals

Next Previous
X
Search
Drug Profile

Volixibat - Mirum Pharmaceuticals

Alternative Names: LUM-002; SAR-548304; SHP-626; Volixibat - Takeda; Volixibat potassium

Latest Information Update: 14 Oct 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator sanofi-aventis
  • Developer Mirum Pharmaceuticals; Sanofi; Shire
  • Class Anti-inflammatories; Antihyperlipidaemics; Benzothiepins; Hepatoprotectants; Urea compounds
  • Mechanism of Action Sodium-bile acid cotransporter inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Primary biliary cirrhosis
  • Phase II Intrahepatic cholestasis; Primary sclerosing cholangitis
  • No development reported Cholestasis
  • Discontinued Hypercholesterolaemia; Non-alcoholic steatohepatitis

Most Recent Events

  • 10 Oct 2024 Volixibat - Mirum Pharmaceuticals receives Breakthrough Therapy status for Primary biliary cirrhosis in USA
  • 17 Jul 2024 Phase-II clinical trials in Primary sclerosing cholangitis in Argentina, Belgium, Italy, Netherlands (PO) (NCT04663308)
  • 03 Jul 2024 Phase-II clinical trials in Primary biliary cirrhosis in Spain (PO) (NCT05050136)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top